<DOC>
	<DOCNO>NCT01991366</DOCNO>
	<brief_summary>The aim observational study evaluate hospital 6 month outcome use Glycoprotein IIb/IIIa inhibitor eptifibatide adjunctive therapy patient undergoing primary Percutaneous Coronary Intervention ST-elevation myocardial infarction large tertiary referral center . It hypothesize Glycoprotein IIb/IIIa inhibitor use primary Percutaneous Coronary Intervention ST-elevation myocardial infarction/ acute myocardial infarction superior unfractionated heparin alone bivalirudin alone . Additionally , propensity matching superiority remain .</brief_summary>
	<brief_title>Should Integrilin Integral Part Adjunctive Therapy Patients Undergoing Primary PCI ST-Elevation MI ?</brief_title>
	<detailed_description>This retrospective , observational , data analysis approximately 800 patient underwent primary Percutaneous Coronary Intervention institution since September 2000 . Patients either receive eptifibatide pre-or Percutaneous Coronary Intervention receive eptifibatide . Patients receive thrombolytic prior Percutaneous Coronary Intervention exclude . This analysis estimate take 1-2 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Underwent Percutaneous Coronary Intervention Washington Hospital Center since September 2000 Either receive eptifibatide preor PCI receive eptifibatide . Patients receive thrombolytic prior Percutaneous Coronary Intervention .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Major adverse microvascular integrity</keyword>
	<keyword>cause mortality</keyword>
	<keyword>Q Wave MI</keyword>
</DOC>